Compare UAMY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAMY | VTYX |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.9M |
| IPO Year | 1997 | 2021 |
| Metric | UAMY | VTYX |
|---|---|---|
| Price | $10.47 | $13.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | $7.69 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 10.0M | 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.67 | 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,937,962.00 | N/A |
| Revenue This Year | $164.09 | N/A |
| Revenue Next Year | $218.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.84 | N/A |
| 52 Week Low | $1.21 | $0.90 |
| 52 Week High | $19.71 | $15.34 |
| Indicator | UAMY | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 71.25 |
| Support Level | $6.57 | $13.89 |
| Resistance Level | $11.97 | $14.07 |
| Average True Range (ATR) | 0.82 | 0.03 |
| MACD | 0.21 | -0.12 |
| Stochastic Oscillator | 96.35 | 66.67 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.